We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-12.93%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$102B
AUM Growth
-$16.3B
Cap. Flow
+$749M
Cap. Flow %
0.73%
Top 10 Hldgs %
23.72%
Holding
4,322
New
210
Increased
1,790
Reduced
1,850
Closed
304
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PRGS icon
1901
Progress Software
PRGS
$1.83B
$2.31M ﹤0.01%
51,001
+856
+2% +$40.7K
LSCC icon
1902
Lattice Semiconductor
LSCC
$18.2B
$2.31M ﹤0.01%
47,574
-503
-1% -$25.1K
PNR icon
1903
Pentair
PNR
$10.7B
$2.31M ﹤0.01%
50,369
-53,962
-52% -$2.7M
RNR icon
1904
RenaissanceRe
RNR
$13.3B
$2.3M ﹤0.01%
14,737
+209
+1% +$31.6K
SMPL icon
1905
Simply Good Foods
SMPL
$989M
$2.3M ﹤0.01%
60,862
+15,319
+34% +$607K
TXG icon
1906
10x Genomics
TXG
$7.58B
$2.3M ﹤0.01%
50,805
-2,204
-4% -$114K
TBCH
1907
Turtle Beach Corp
TBCH
$230M
$2.3M ﹤0.01%
187,793
+29,317
+18% +$499K
STVN icon
1908
Stevanato
STVN
$5.88B
$2.29M ﹤0.01%
145,137
+71,694
+98% +$1.18M
GTIP icon
1909
Goldman Sachs Access Inflation Protected USD Bond ETF
GTIP
$296M
$2.29M ﹤0.01%
44,405
-5,322
-11% -$286K
WDFC icon
1910
WD-40
WDFC
$3.09B
$2.29M ﹤0.01%
11,360
+170
+2% +$31.7K
HZO icon
1911
MarineMax
HZO
$1.15B
$2.28M ﹤0.01%
63,242
-4,064
-6% -$163K
IART icon
1912
Integra LifeSciences
IART
$1.42B
$2.28M ﹤0.01%
42,242
+1,785
+4% +$107K
PCRX icon
1913
Pacira BioSciences
PCRX
$924M
$2.28M ﹤0.01%
39,086
+3,787
+11% +$248K
VNOM icon
1914
Viper Energy
VNOM
$14.8B
$2.27M ﹤0.01%
84,954
+38,282
+82% +$1.16M
TSE
1915
DELISTED
Trinseo
TSE
$2.25M ﹤0.01%
58,500
+5,787
+11% +$262K
KNX icon
1916
Knight Transportation
KNX
$11.9B
$2.25M ﹤0.01%
48,528
-27,867
-36% -$1.32M
IIIV icon
1917
i3 Verticals
IIIV
$325M
$2.24M ﹤0.01%
89,675
-31,424
-26% -$792K
FTXL icon
1918
First Trust Nasdaq Semiconductor ETF
FTXL
$1.38B
$2.24M ﹤0.01%
42,204
-40,792
-49% -$2.46M
PREF icon
1919
Principal Spectrum Preferred Securities Active ETF
PREF
$1.78B
$2.24M ﹤0.01%
129,898
-41,829
-24% -$754K
MAXR
1920
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
$2.24M ﹤0.01%
85,911
+426
+0.5% +$13.3K
RUSHA icon
1921
Rush Enterprises Class A
RUSHA
$9.62B
$2.24M ﹤0.01%
69,575
+773
+1% +$25.8K
GSST icon
1922
Goldman Sachs Access Ultra Short Bond ETF
GSST
$1.59B
$2.23M ﹤0.01%
44,780
+7,892
+21% +$395K
ASO icon
1923
Academy Sports + Outdoors
ASO
$3.03B
$2.21M ﹤0.01%
62,170
+20,342
+49% +$744K
DGT icon
1924
State Street SPDR Global Dow ETF
DGT
$631M
$2.21M ﹤0.01%
22,975
-2,285
-9% -$240K
GRID
1925
First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund
GRID
$12.3B
$2.21M ﹤0.01%
28,437
-4,272
-13% -$362K

Similar funds

Raymond James & Associates's Q2 2022 Portfolio in Review

As of Q2 2022, Raymond James & Associates held 4,322 positions worth $102B, down 14% from $119B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q2 2022 filing shows 210 new, 1,790 increased, 1,850 reduced and 304 closed positions. Its largest new stake was Aspen Technology Inc: 54,037 shares worth $9.93M. The largest sale was iShares Core MSCI EAFE ETF, an estimated $551M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 15% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q2 2022 buy was Aspen Technology Inc: 54,037 shares worth $9.93M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q2 2022, an estimated $471M increase.
  • Raymond James & Associates's biggest Q2 2022 reduction was iShares Core MSCI EAFE ETF, cutting an estimated $551M.
  • Raymond James & Associates fully exited ASPEN TECHNOLOGY INC in Q2 2022, selling an estimated $21.5M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $102B portfolio in Q2 2022.
  • Raymond James & Associates opened 210 new positions and closed 304 in Q2 2022.
  • Raymond James & Associates's portfolio value fell 14% quarter-over-quarter to $102B.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.